Olprinone HCl | CAS#119615-63-3 | 106730-54-5 | PDE-III inhibitor

MedKoo Cat#: 326772 | Name: Olprinone HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Olprinone (INN) is a cardiotonic agent and a specific phosphodiesterase (PDE)-III inhibitor. It has been marketed in Japan since 1996. Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model. Olprinone reduces the development of multiple organ dysfunction syndrome in mice.

Chemical Structure

Olprinone HCl

CAS#119615-63-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 326772

Name: Olprinone HCl

CAS#: 119615-63-3 (HCl)

Chemical Formula: C14H11ClN4O

Exact Mass: 0.0000

Molecular Weight: 286.72

Elemental Analysis: C, 58.65; H, 3.87; Cl, 12.36; N, 19.54; O, 5.58

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 550.00
50mg	USD 1,200.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

119615-63-3 (HCl) 106730-54-5 (free base)

Synonym

Olprinone hydrochloride; Olprinone; Olprinone HCl;

IUPAC/Chemical Name

5-(imidazo[1,2-a]pyridin-6-yl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile hydrochloride.

InChi Key

PWTBMBAQRAOAFF-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H10N4O.ClH/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10;/h2-6,8H,1H3,(H,17,19);1H

SMILES Code

N#CC1=CC(C2=CN3C(C=C2)=NC=C3)=C(C)NC1=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Olprinone (INN) is a cardiotonic agent and a specific phosphodiesterase (PDE)-III inhibitor.

In vitro activity:

Olprinone at 30-1000 nM increased the protein level of Kv1.5 channels in a concentration-dependent manner. Chase experiments showed that olprinone delayed degradation of Kv1.5 channels. Olprinone increased the immunofluorescent signal of Kv1.5 channels in the endoplasmic reticulum (ER) and Golgi apparatus as well as on the cell surface. Kv1.5-mediated membrane currents, measured as 4-aminopyridine-sensitive currents, were increased by olprinone without changes in their activation kinetics. Reference: Eur J Pharmacol. 2015 Oct 15;765:488-94. https://pubmed.ncbi.nlm.nih.gov/26368666/

In vivo activity:

This study aimed to investigate whether a selective phosphodiesterase-3 (PDE3) inhibitor olprinone can positively influence the inflammation, apoptosis, and respiratory parameters in animals with acute respiratory distress syndrome (ARDS) model induced by repetitive saline lung lavage. Adult rabbits were divided into 3 groups: ARDS without therapy (ARDS), ARDS treated with olprinone i.v. (1 mg/kg; ARDS/PDE3), and healthy ventilated controls (Control), and were oxygen-ventilated for the following 4 h. Treatment with olprinone reduced the release of inflammatory mediators and markers of oxidative damage decreased apoptosis of epithelial cells and improved respiratory parameters. Reference: Int J Mol Sci. 2020 May 11;21(9):3382. https://pubmed.ncbi.nlm.nih.gov/32403267/

	Solvent	mg/mL	mM
Solubility
	Water	7.7	26.82

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 286.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Endo R, Kurata Y, Notsu T, Li P, Morikawa K, Kondo T, Ogura K, Miake J, Yoshida A, Shirayoshi Y, Ninomiya H, Higaki K, Kuwabara M, Yamamoto K, Inagaki Y, Hisatome I. Stabilization of Kv1.5 channel protein by the inotropic agent olprinone. Eur J Pharmacol. 2015 Oct 15;765:488-94. doi: 10.1016/j.ejphar.2015.09.013. Epub 2015 Sep 12. PMID: 26368666. 2. Okayama N, Matsunaga A, Kakihana Y, Fujikawa K, Inoue K, Nagayama T, Takeyama M, Miyata A, Kanmura Y. The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia. Anesth Analg. 2010 Mar 1;110(3):888-94. doi: 10.1213/ANE.0b013e3181cb5cdd. Epub 2009 Dec 30. PMID: 20042441. 3. Kosutova P, Mikolka P, Balentova S, Adamkov M, Calkovska A, Mokra D. Effects of PDE3 Inhibitor Olprinone on the Respiratory Parameters, Inflammation, and Apoptosis in an Experimental Model of Acute Respiratory Distress Syndrome. Int J Mol Sci. 2020 May 11;21(9):3382. doi: 10.3390/ijms21093382. PMID: 32403267; PMCID: PMC7247002. 4. Han MX, Xu XW, Lu SQ, Zhang GX. Effect of olprinone on ischemia-reperfusion induced myocardial injury in rats. Biomed Pharmacother. 2019 Mar;111:1005-1012. doi: 10.1016/j.biopha.2019.01.010. Epub 2019 Jan 10. PMID: 30841413.

In vitro protocol:

In vivo protocol:

1. Kosutova P, Mikolka P, Balentova S, Adamkov M, Calkovska A, Mokra D. Effects of PDE3 Inhibitor Olprinone on the Respiratory Parameters, Inflammation, and Apoptosis in an Experimental Model of Acute Respiratory Distress Syndrome. Int J Mol Sci. 2020 May 11;21(9):3382. doi: 10.3390/ijms21093382. PMID: 32403267; PMCID: PMC7247002. 2. Han MX, Xu XW, Lu SQ, Zhang GX. Effect of olprinone on ischemia-reperfusion induced myocardial injury in rats. Biomed Pharmacother. 2019 Mar;111:1005-1012. doi: 10.1016/j.biopha.2019.01.010. Epub 2019 Jan 10. PMID: 30841413.

1: Endo R, Kurata Y, Notsu T, Li P, Morikawa K, Kondo T, Ogura K, Miake J, Yoshida A, Shirayoshi Y, Ninomiya H, Higaki K, Kuwabara M, Yamamoto K, Inagaki Y, Hisatome I. Stabilization of Kv1.5 channel protein by the inotropic agent olprinone. Eur J Pharmacol. 2015 Oct 15;765:488-94. doi: 10.1016/j.ejphar.2015.09.013. Epub 2015 Sep 12. PubMed PMID: 26368666. 2: Nojiri T, Yamamoto K, Maeda H, Takeuchi Y, Ose N, Susaki Y, Inoue M, Okumura M. A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer. Chest. 2015 Nov;148(5):1285-92. doi: 10.1378/chest.15-0852. PubMed PMID: 26204331. 3: Iguchi K, Hatano E, Yamanaka K, Sato M, Yamamoto G, Kasai Y, Okamoto T, Okuno M, Taura K, Fukumoto K, Ueno K, Uemoto S. Hepatoprotective effect by pretreatment with olprinone in a swine partial hepatectomy model. Liver Transpl. 2014 Jul;20(7):838-49. doi: 10.1002/lt.23884. Epub 2014 May 26. PubMed PMID: 24700629. 4: Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H. Population pharmacokinetics of olprinone in healthy male volunteers. Clin Pharmacol. 2014 Mar 4;6:43-50. doi: 10.2147/CPAA.S50626. eCollection 2014. PubMed PMID: 24623995; PubMed Central PMCID: PMC3949558. 5: Mokra D, Tonhajzerova I, Pistekova H, Visnovcova Z, Mokry J, Drgova A, Repcakova M, Calkovska A. Short-term cardiovascular effects of selective phosphodiesterase 3 inhibitor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in a meconium-induced acute lung injury. J Physiol Pharmacol. 2013 Dec;64(6):751-9. PubMed PMID: 24388890. 6: Sakimura S, Yoshino J, Izumi K, Jimi N, Sumiyoshi R, Mizuno K. [Comparison of the effects of phosphodiesterase III inhibitors, milrinone and olprinone, in infant corrective cardiac surgery]. Masui. 2013 May;62(5):583-8. Japanese. PubMed PMID: 23772533. 7: Wang H, Zhang B, Sun X, Sun Y, Shi M. Method development and validation of olprinone in human plasma by HPLC coupled with ESI-MS-MS: application to a pharmacokinetic study. J Chromatogr Sci. 2014 May-Jun;52(5):400-5. doi: 10.1093/chromsci/bmt049. Epub 2013 May 19. PubMed PMID: 23690065. 8: Retraction note to: Different effects of olprinone on contractility in nonfatigued and fatigued diaphragm in dogs. Can J Anaesth. 2013 Jun;60(6):610. doi: 10.1007/s12630-013-9945-3. Epub 2013 Apr 26. PubMed PMID: 23619612. 9: The effect of olprinone compared with milrinone on diaphragmatic muscle function in dogs. Anesth Analg 1999;89:781-5. Retraction. Anesth Analg. 2013 Mar;116(3):745. doi: 10.1213/ANE.0b013e31828ac3d7. PubMed PMID: 23439829. 10: Yamanaka K, Hatano E, Iguchi K, Yamamoto G, Sato M, Toriguchi K, Tanabe K, Takemoto K, Nakamura K, Koyama N, Narita M, Nagata H, Taura K, Uemoto S. Effect of olprinone on liver microstructure in rat partial liver transplantation. J Surg Res. 2013 Jul;183(1):391-6. doi: 10.1016/j.jss.2012.11.033. Epub 2012 Dec 8. PubMed PMID: 23246009. 11: Tsubokawa T, Ishizuka S, Fukumoto K, Ueno K, Yamamoto K. The effect of hemodilution by cardiopulmonary bypass on protein binding of olprinone. J Anesth. 2013 Jun;27(3):346-50. doi: 10.1007/s00540-012-1524-1. Epub 2012 Nov 23. PubMed PMID: 23179741. 12: Tsubokawa T, Ishizuka S, Fukumoto K, Ueno K, Yamamoto K. Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass. J Anesth. 2013 Apr;27(2):243-50. doi: 10.1007/s00540-012-1505-4. Epub 2012 Oct 23. PubMed PMID: 23090059. 13: Tachikawa M, Shimazaki M, Arai T, Saima S, Adachi E, Okuda Y. [Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting]. Masui. 2012 Jun;61(6):566-73. Japanese. PubMed PMID: 22746016. 14: Oishi H, Takano K, Tomita K, Takebe M, Yokoo H, Yamazaki M, Hattori Y. Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway. Am J Physiol Lung Cell Mol Physiol. 2012 Jul;303(2):L130-40. doi: 10.1152/ajplung.00363.2011. Epub 2012 May 18. PubMed PMID: 22610350. 15: Mokra D, Drgova A, Pullmann R Sr, Calkovska A. Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury. Pulm Pharmacol Ther. 2012 Jun;25(3):216-22. doi: 10.1016/j.pupt.2012.02.007. Epub 2012 Feb 25. PubMed PMID: 22387424. 16: Genovese T, Mazzon E, Paterniti I, Esposito E, Cuzzocrea S. Neuroprotective effects of olprinone after cerebral ischemia/reperfusion injury in rats. Neurosci Lett. 2011 Oct 3;503(2):93-9. doi: 10.1016/j.neulet.2011.08.015. Epub 2011 Aug 17. PubMed PMID: 21872644. 17: Zhou J, Iwasaki S, Watanabe A, Yamakage M. Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs. Eur J Anaesthesiol. 2011 Jul;28(7):519-24. doi: 10.1097/EJA.0b013e3283463f4a. PubMed PMID: 21494151. 18: Yamanaka H, Hayashi Y, Kamibayashi T, Mashimo T. Effect of olprinone, a phosphodiesterase III inhibitor, on balance of cerebral oxygen supply and demand during cardiopulmonary bypass. J Cardiovasc Pharmacol. 2011 May;57(5):579-83. doi: 10.1097/FJC.0b013e3182135dbf. PubMed PMID: 21326107. 19: Yamanaka K, Hatano E, Narita M, Kitamura K, Yanagida A, Asechi H, Nagata H, Taura K, Nitta T, Uemoto S. Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model. Liver Transpl. 2011 Jan;17(1):60-9. doi: 10.1002/lt.22189. PubMed PMID: 21254346. 20: Mazzon E, Esposito E, Di Paola R, Impellizzeri D, Bramanti P, Cuzzocrea S. Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice. Pharmacol Res. 2011 Jul;64(1):68-79. doi: 10.1016/j.phrs.2010.12.010. Epub 2010 Dec 28. PubMed PMID: 21193041.